Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach

Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data

(2021) Gudrun Würthwein et al.   EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

Prospective, real‐time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non‐Hodgkin lymphoma in Belgium

(2020) Veerle Mondelaers et al.   BRITISH JOURNAL OF HAEMATOLOGY

Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia

(2020) Robin Q.H. Kloos et al.   JOURNAL OF CLINICAL ONCOLOGY

Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model

(2020) Robin Q.H. Kloos et al.   HAEMATOLOGICA

Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children’s Oncology Group

(2020) Sumit Gupta et al.   JOURNAL OF CLINICAL ONCOLOGY

Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia

(2020) Alaeddin Khalil et al.   HAEMATOLOGICA

Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia

(2020) Sofie Gottschalk Højfeldt et al.   BLOOD

Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with PEG-Asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study.

(2019) Carmelo Rizzari et al.   HAEMATOLOGICA

Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge

(2019) Yiwei Liu et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0331

(2019) Kelly W. Maloney et al.   JOURNAL OF CLINICAL ONCOLOGY

Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar® in Children with Acute Lymphoblastic Leukemia

(2017) Gudrun Würthwein et al.   EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation

(2017) Louise Tram Henriksen et al.   PEDIATRIC BLOOD & CANCER

A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia

(2017) Robin Q.H. Kloos et al.   PEDIATRIC BLOOD & CANCER

Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn’s Disease Is Determined by Their Concentration

(2016) Helena Edlund et al.   AAPS Journal

Impact of anti-PEG IgM antibodies on the pharmacokinetics of pegylated asparaginase preparations in mice

(2016) Sabine M. Poppenborg et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation

(2016) I. M. van der Sluis et al.   HAEMATOLOGICA

Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation

(2016) I. M. van der Sluis et al.   HAEMATOLOGICA

Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report

(2015) Richard H. Ko et al.   CANCER

Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial

(2015) Andrew E Place et al.   LANCET ONCOLOGY

A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia

(2014) Wing H. Tong et al.   BLOOD

Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial

(2014) Nicola Longo et al.   LANCET

Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients

(2014) Michael S Hershfield et al.   ARTHRITIS RESEARCH & THERAPY